| Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1) (NCT05103358) | Aadi Bioscience, Inc. | 2022-02-15 |
| Cohort of Tumors With POLE/D1 Mutation (NCT05103969) | Federation Francophone de Cancerologie Digestive | 2021-10-05 |
| Research on the Application and Mechanism of New Biological Probes in Biomedicine (NCT04977739) | Nanfang Hospital, Southern Medical University | 2021-08-03 |
| CDK4/6 Tumor, Abemaciclib, Paclitaxel (NCT04594005) | Yonsei University | 2021-02-25 |
| ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling (NCT04341181) | Ulrik Lassen | 2020-08-24 |
| A Study to Assess the Safety and Efficacy of ASP1650, a Monoclonal Antibody Targeting Claudin 6 (CLDN6), in Male Subjects With Incurable Platinum Refractory Germ Cell Tumors (NCT03760081) | Astellas Pharma Global Development, Inc. | 2019-03-19 |
| Assessment of Functional and Symptom Outcomes for Survivors of Paranasal Sinus, Nasopharyngeal and Skull Base Tumors (NCT05733091) | M.D. Anderson Cancer Center | 2018-12-20 |
| A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors (NCT03251924) | Bristol-Myers Squibb | 2017-09-01 |
| Safety of TAS-102 in Combination With Temozolomide for Metastatic Pancreatic NETs (NCT02943733) | University of Wisconsin, Madison | 2017-08-22 |
| Safety and Pharmacokinetic Study of IT-141 in Monotherapy in Patients With Advanced Cancer (NCT03096340) | Intezyne Technologies, Inc. | 2017-03-23 |
| Assay Development for Cancer Biomarkers (NCT02874729) | King's College London | 2016-11-01 |
| The Drug Rediscovery Protocol (DRUP Trial) (NCT02925234) | The Netherlands Cancer Institute | 2016-08-01 |
| Point of Care 3D Ultrasound for Various Applications: A Pilot Study (NCT02831556) | Duke University | 2016-07-01 |
| Phase 1 Study to Determine the Effect of Lenvatinib (E7080) on the Pharmacokinetics of Midazolam in Subjects With Advanced Solid Tumors (NCT02686164) | Eisai Inc. | 2016-04-18 |
| A Phase I Study of PLX038 in Patients With Advanced Solid Tumors (NCT02646852) | ProLynx LLC | 2016-03-01 |
| A Multi-Center, Open-Label Study of Surufatinib (HMPL-012) in Patients With Advanced Solid Tumors (NCT02549937) | Hutchmed | 2015-11-01 |
| Ramosetron, Aprepitant, and Dexamethasone Versus Palonosetron, Aprepitant, and Dexamethasone (NCT02532634) | Kangdong Sacred Heart Hospital | 2015-08-19 |
| Study of E7046 in Subjects With Selected Advanced Malignancies (NCT02540291) | Eisai Inc. | 2015-07-30 |
| A Trial of Lenvatinib (E7080) Plus Pembrolizumab in Participants With Selected Solid Tumors (NCT02501096) | Eisai Inc. | 2015-07-22 |
| A Study of Atezolizumab in Advanced Solid Tumors (NCT02458638) | Hoffmann-La Roche | 2015-07-16 |
| Safety Study of AMG 228 to Treat Solid Tumors (NCT02437916) | Amgen | 2015-04-21 |
| Data Collection in Patients Undergoing CT-Guided Needle Interventions for NeedleWays System Development (NCT02329665) | NeedleWays | 2015-02-01 |
| Ph Ib/BGJ398/Cervix and Other Solid Tumors (NCT02312804) | The University of Texas Health Science Center at San Antonio | 2015-01-01 |
| Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With Osteosarcoma (NCT02432274) | Eisai Limited | 2014-12-29 |
| A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma (NCT02110355) | Kartos Therapeutics, Inc. | 2014-12-19 |
| Phase 1 Study of E7090 in Subjects With Solid Tumor (NCT02275910) | Eisai Co., Ltd. | 2014-10-28 |
| to evaluate188Re-BMEDA-liposome in Patient With Primary Solid Tumor in Advanced or Metastatic Stage (NCT02271516) | National Atomic Research Institute, Taiwan | 2014-10-01 |
| Perioperative Risk Study (NCT02456389) | Fox Chase Cancer Center | 2014-08-01 |
| Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors (NCT01962103) | Celgene | 2013-12-04 |
| Phase I Study of the Volitinib (HMPL-504) in Patients With Advanced Solid Tumors (NCT01985555) | Hutchison Medipharma Limited | 2013-05-01 |
| Biomarker Breast Pap Test (NCT01683305) | Silbiotech | 2013-03-01 |
| Phase I Study of LB-100 With Docetaxel in Solid Tumors (NCT01837667) | Lixte Biotechnology Holdings, Inc. | 2013-02-01 |
| A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma (NCT01723020) | Kartos Therapeutics, Inc. | 2012-12-27 |
| Phase I/II Study of APS001F With Flucytosine and Maltose in Solid Tumors (NCT01562626) | Anaeropharma Science, Inc. | 2012-09-01 |
| A Phase I Study of OSI-906 in Combination With Pemetrexed in Advanced Solid Tumor Malignancies (NCT01567384) | Emory University | 2012-05-01 |
| Clinic Study of 18F-Al-NOTA-PRGD2 in Cancer Diagnostics (NCT02441972) | Wuxi No. 4 People's Hospital | 2012-01-01 |
| Evaluation of Plasma Alcohol Concentration in Patients Receiving Paclitaxel or Docetaxel (NCT01448759) | Institut Curie | 2011-10-01 |
| A Study of the Safety and Pharmacokinetics of AGS-22M6E in Subjects With Malignant Solid Tumors That Express Nectin-4 (NCT01409135) | Astellas Pharma Inc | 2011-07-11 |
| A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PDL1] Antibody) to Evaluate Safety, Tolerability and Pharmacokinetics in Participants With Locally Advanced or Metastatic Solid Tumors (NCT01375842) | Genentech, Inc. | 2011-06-21 |
| AMG 319 Lymphoid Malignancy FIH (NCT01300026) | Amgen | 2011-04-01 |
| MK-2206, Paclitaxel and Trastuzumab in Treating Patients With HER2-overexpressing Solid Tumor Malignancies (NCT01235897) | University of California, San Francisco | 2011-03-01 |
| Kypho-IORT: Intraoperative Radiotherapy During Kyphoplasty for Spinal Metastases (NCT01280032) | Universitätsmedizin Mannheim | 2011-01-01 |
| A Study of AMG 337 in Subjects With Advanced Solid Tumors (NCT01253707) | Amgen | 2010-12-08 |
| 18F-Fluorodeoxyglucose Positron Emission Tomography in Oncology and Neurology (NCT01180751) | University of Manitoba | 2010-07-01 |
| Bioavailability and Food Effect Study of TKI258 (CSF Capsule vs. FMI Tablet) in Adult Patients With Advanced Solid Tumors (NCT01155713) | Novartis Pharmaceuticals | 2010-07-01 |
| Comparison of the Cosmetic Outcome of Hypofractionated Versus Normofractionated IMRT in Treatment of Breast Cancer (NCT01403779) | Universitätsmedizin Mannheim | 2010-07-01 |
| Proton Radiotherapy for Recurrent Tumors (NCT01126476) | Abramson Cancer Center at Penn Medicine | 2010-02-01 |
| Bioavailability and Food Effect Study of TKI258 (CSF Capsules vs. FMI Capsules)in Adult Patients With Advanced Solid Tumors (NCT01030055) | Novartis Pharmaceuticals | 2010-02-01 |
| ASA404 in Combination With Carboplatin/Paclitaxel/Cetuximab in Treating Patients With Refractory Solid Tumors (NCT01031212) | University of California, San Francisco | 2010-01-01 |
| A Study of IMC-A12 in Advanced Solid Tumors (NCT01007032) | Eli Lilly and Company | 2009-11-01 |
| A Phase 1 First-in-Human Study Evaluating AMG 900 in Advanced Solid Tumors (NCT00858377) | Amgen | 2009-08-10 |
| Phase I Study to Investigate Pharmacokinetics and Safety of BAY73-4506 in Asian (Japanese) Patients With Solid Tumors. (NCT00960258) | Bayer | 2009-07-01 |
| Reduced Pancreatic Fistula Rate Following Pancreaticoduodenectomy: Trial on Pancreaticogastrostomy Versus Pancreaticojejunostomy (NCT00830778) | Baki Topal | 2009-06-01 |
| Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer (NCT00807859) | Amgen | 2009-03-09 |
| Randomized, Double Blind, Placebo-controlled Topical Resiquimod Adjuvant for NY-ESO-1 Protein Vaccination (NCT00821652) | Nina Bhardwaj | 2009-02-01 |
| Extension Study to Evaluate Long Term Safety of Denosumab in Subjects Undergoing ADT for Non-Metastatic Prostate Cancer (NCT00838201) | Amgen | 2009-02-01 |
| A Study to Evaluate Biomarkers in Patients With Solid Tumors (0000-097)(COMPLETED) (NCT00800865) | Merck Sharp & Dohme LLC | 2009-01-01 |
| AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR (NCT00770536) | Amgen | 2009-01-01 |
| A Phase 1 Study of AMG 208 in Subjects With Advanced Solid Tumors (NCT00813384) | Amgen | 2008-12-01 |
| A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of CUDC-101 in Patients With Advanced Solid Tumors (NCT00728793) | Curis, Inc. | 2008-08-01 |
| Study Evaluating Ascending Single-Dose Of Bosutinib Administered With Multiple Doses Of Ketoconazole To Healthy Subjects (NCT00777530) | Wyeth is now a wholly owned subsidiary of Pfizer | 2008-04-01 |
| A Study of AMG 820 in Subjects With Advanced Solid Tumors (NCT01444404) | AmMax Bio, Inc. | 2008-03-31 |
| A Phase I, Dose-Escalation Study to Assess the Safety and Drug Levels in Blood of AZD4877 in Japanese Adult Patients (NCT00613652) | AstraZeneca | 2008-01-01 |
| Optimal Application Dose of Superficial Hyperthermia (NCT00766233) | Universitätsmedizin Mannheim | 2008-01-01 |
| PRISM (Panitumumab Regimen In Second-line Monotherapy of Head and Neck Cancer) (NCT00446446) | Amgen | 2007-10-30 |
| A Phase I Study to Determine Absorption, Distribution, Metabolism, and Elimination of a Single Radiolabeled Dose of Brivanib (BMS-582664) (NCT00435669) | Bristol-Myers Squibb | 2007-09-01 |
| A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of TH-302 in Patients With Advanced Solid Tumors (NCT00495144) | Threshold Pharmaceuticals | 2007-06-01 |
| An Open-Label Study of YM155 + Docetaxel in Subjects With Advanced Hormone Refractory Prostate Cancer and Other Solid Tumors (NCT00514267) | Astellas Pharma Inc | 2007-05-01 |
| Study of Satraplatin (JM-216) in Combination With Docetaxel (NCT00125411) | Agennix | 2007-03-01 |
| Study of Dasatinib (BMS-354825) in Patients With Solid Tumors (NCT00339144) | Bristol-Myers Squibb | 2007-01-01 |
| Dose Escalation Study of SH U04722 in Solid Tumors (NCT00375453) | Bayer | 2007-01-01 |
| QUILT-2.016: Study of AMG 479 With Biologics or Chemotherapy for Subjects With Advanced Solid Tumors (NCT00974896) | NantCell, Inc. | 2006-12-01 |
| Oral Topotecan to Treat Recurrent or Persistent Solid Tumors (NCT00382733) | Accelerated Community Oncology Research Network | 2006-11-01 |
| LBH589 in Adult Patients With Advanced Solid Tumors or Cutaneous T-cell Lymphoma (NCT00412997) | Novartis | 2006-11-01 |
| Phase I Study of Perifosine + Sorafenib for Patients With Advanced Cancers (NCT00398814) | AEterna Zentaris | 2006-10-01 |
| Study of AR-67 (Formerly DB-67) in Adult Patients With Refractory or Metastatic Solid Malignancies (NCT00389480) | Arno Therapeutics | 2006-10-01 |
| A Phase 1, Open-Label, Randomized, Cross-Over, Pharmacokinetic Study Evaluating the Effect of S-1 on Advanced Solid Tumors (NCT00400023) | Taiho Oncology, Inc. | 2006-09-01 |
| A Phase I/II Study of MGCD0103 (MG-0103) in Combination With Gemcitabine (NCT00372437) | Mirati Therapeutics Inc. | 2006-09-01 |
| Safety Study of Increasing Doses of Combretastatin in Combination With Bevacizumab (Avastin) in Patients With Advanced Solid Tumors (NCT00395434) | Mateon Therapeutics | 2006-09-01 |
| Rapamycin With Grapefruit Juice for Advanced Malignancies (NCT00375245) | University of Chicago | 2006-09-01 |
| Pegfilgrastim Versus Filgrastim After High-dose Chemotherapy (NCT00410696) | Armando Santoro, MD | 2006-09-01 |
| Efficacy and Safety of Patupilone in Patients With Advanced Solid Tumors in Japan (NCT00412789) | Novartis Pharmaceuticals | 2006-08-01 |
| Study of Vinorelbine Liposomes Injection for Advanced Solid Tumors, Non-Hodgkin's Lymphoma or Hodgkin's Disease (NCT00364676) | Spectrum Pharmaceuticals, Inc | 2006-07-01 |
| One Time Injection of Bacteria to Treat Solid Tumors That Have Not Responded to Standard Therapy (NCT00358397) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2006-07-01 |
| A Study of Oral Suberoylanilide Hydroxamic Acid (Vorinostat) in Patients With Solid Tumors (0683-048) (NCT00373490) | Merck Sharp & Dohme LLC | 2006-07-01 |
| A Dose-escalation Study of BIBF 1120 in Japanese Patients With Advanced Solid Tumours (NCT02182128) | Boehringer Ingelheim | 2006-06-01 |
| Administration of High Dose Thiotepa and Melphalan With Autologous Hematopoietic Stem Cell Transplant in Children and Adolescents With Solid Tumors (NCT00607984) | Rabin Medical Center | 2006-06-01 |
| AZD1152 in Patients With Advanced Solid Malignancies (NCT00338182) | AstraZeneca | 2006-05-23 |
| A Study of Patupilone in Patients With Advanced Solid Tumors and Varying Degrees of Hepatic Function (NCT00421044) | Novartis Pharmaceuticals | 2006-05-01 |
| NY-ESO-1 Protein With Montanide and CpG 7909 as Cancer Vaccine in Several Tumors (NCT00299728) | Ludwig Institute for Cancer Research | 2006-03-21 |
| Phase 1/1b Dose Escalation Study Evaluating BSI-201 as a Single Agent and in Combination With Irinotecan in Subjects With Advanced Solid Tumors (NCT00298675) | Sanofi | 2006-03-01 |
| A Phase I Study of ECO-4601 in Patients With Advanced Cancer (NCT00338026) | Thallion Pharmaceuticals | 2006-02-01 |
| Study Evaluating SKI-606 in Subject With Solid Tumors (NCT01001936) | Wyeth is now a wholly owned subsidiary of Pfizer | 2006-02-01 |
| Study of Combination of Sirolimus and Sutent in Patients With Advanced Solid Tumors Non-Curable With Standard Therapy (NCT00402415) | Yale University | 2006-02-01 |
| Study of Oral CNF2024 (BIIB021) in Advanced Solid Tumors (NCT00345189) | Biogen | 2006-02-01 |
| A Study of Patupilone in Patients With Advanced Solid Tumors and Varying Degrees of Hepatic Function (NCT00420524) | Novartis Pharmaceuticals | 2006-01-01 |
| Safety Assessment of One-hour Infusions of SNS-032 for the Treatment of Select Advanced Solid Tumors (NCT00292864) | Sunesis Pharmaceuticals | 2006-01-01 |
| Study of BMS-663513 in Patients With Advanced Cancer (NCT00309023) | Bristol-Myers Squibb | 2005-12-01 |
| Study to Investigate the Management of Hypertension and Efficacy of AZD2171 in Patients With Advanced Solid Tumours (NCT00264004) | AstraZeneca | 2005-11-01 |
| INNO-105 in Patients With Solid Tumors (NCT00255333) | Innovive Pharmaceuticals | 2005-11-01 |